Seaport Therapeutics is building a fail-safe into its Phase 2b depression trial.
The biotech is testing its drug, called SPT-300, in patients with major depressive disorder. But executives believe SPT-300 could prove more promising in …
Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline. The drug litifilimab
Tanabe Pharma unveiled positive data from a Phase 3 trial of its oral drug for a pair of rare diseases, its first major clinical milestone
Welcome back to Endpoints Weekly! Our team tracked a handful of deals announced this week as the first quarter comes to a close. Check below
Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide
The European Medicines Agency’s human medicines committee has recommended the approval of four new drugs and a new form of Sanofi’s multiple myeloma drug. CHMP
Seaport Therapeutics is building a fail-safe into its Phase 2b depression trial.
The biotech is testing its drug, called SPT-300, in patients with major depressive disorder. But executives believe SPT-300 could prove more promising in …